Viridian Therapeutics (VRDN) is down -30.8%, or -$8.44 to $18.95.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target lowered to $32 from $42 at Needham
- Viridian Therapeutics price target lowered to $37 from $44 at Wedbush
- Viridian: Buy Rating Backed by Differentiated Elegrobart Profile and Growth Potential in a $2B Thyroid Eye Disease Market
- Viridian Therapeutics falls -33.5%
- Video: Expedia, Instacart pullbacks called buying opportunities